Fig. 4From: Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysisThe forest figure of response rate (CR, PR, SD, PD) on MMR-MSI subgroup analysis. A CR rate on MMR-MSI subgroup analysis. B PR rate on MMR-MSI subgroup analysis. C SD rate on MMR-MSI subgroup analysis. D PD rate on MMR-MSI subgroup analysis. Complete response rate (CR), partial response rate (PR), stable disease rate (SD), progression disease rate (PD)Back to article page